- Home
- E vs ARGX Comparison
E vs ARGX Comparison
Compare E & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- E
- ARGX
- Stock Information
- Founded
- E 1953
- ARGX 2008
- Country
- E Italy
- ARGX Netherlands
- Employees
- E N/A
- ARGX N/A
- Industry
- E Oil & Gas Production
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- E Energy
- ARGX Health Care
- Exchange
- E Nasdaq
- ARGX Nasdaq
- Market Cap
- E 52.3B
- ARGX 44.2B
- IPO Year
- E 1995
- ARGX 2017
- Fundamental
- Price
- E $35.02
- ARGX $756.83
- Analyst Decision
- E Buy
- ARGX Strong Buy
- Analyst Count
- E 4
- ARGX 19
- Target Price
- E $31.60
- ARGX $777.83
- AVG Volume (30 Days)
- E 234.9K
- ARGX 360.8K
- Earning Date
- E 10-24-2025
- ARGX 10-30-2025
- Dividend Yield
- E 4.28%
- ARGX N/A
- EPS Growth
- E N/A
- ARGX N/A
- EPS
- E 0.86
- ARGX 18.75
- Revenue
- E $102,203,170,878.00
- ARGX $3,120,821,000.00
- Revenue This Year
- E N/A
- ARGX $80.01
- Revenue Next Year
- E N/A
- ARGX $30.64
- P/E Ratio
- E $19.81
- ARGX $35.87
- Revenue Growth
- E N/A
- ARGX 88.04
- 52 Week Low
- E $24.65
- ARGX $510.06
- 52 Week High
- E $35.94
- ARGX $779.03
- Technical
- Relative Strength Index (RSI)
- E 52.20
- ARGX 74.39
- Support Level
- E $34.85
- ARGX $745.82
- Resistance Level
- E $35.30
- ARGX $779.03
- Average True Range (ATR)
- E 0.32
- ARGX 14.92
- MACD
- E -0.10
- ARGX 1.39
- Stochastic Oscillator
- E 52.02
- ARGX 74.14
About E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, the company produced 0.8 million barrels of liquids and 4.8 billion cubic feet of natural gas per day. At end-2024, Eni held reserves of 6.5 billion barrels of oil equivalent, 46% of which are liquids. The Italian government owns a 30.5% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plenitude, which it will likely list publicly at some point.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.